×
About 25,738 results

FDA Requests More Restrictions on Ovarian Cancer Drugs
https://www.medscape.com/viewarticle/984547

Nov 23rd, 2022 - The US Food and Drug Administration (FDA) is moving to further restrict the use of certain PARP inhibitors in patients with ovarian cancer, citing recent data showing an increased risk for death with the agents versus chemotherapy. These restrictions could mean bankruptcy for one company. Earlier this year, several companies voluntarily withdrew their respective PARP inhibitors for heavily pret...

International Experts Recommend Actions to End the Pandemic
https://www.medscape.com/viewarticle/984442

Nov 22nd, 2022 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. SARS-CoV-2 still moves among us, requiring continued efforts and resources to save lives. This is the first of six themes outlined in an article published this month in Nature. A multidisciplinary panel of 386 experts from 112 countries and territories was convened to recommend specific actions ...

Dermatologists Predict That Skin Cancer Cases Will Double
https://www.medscape.com/viewarticle/984407

Nov 21st, 2022 - The number of skin cancer cases in men and women increases by 10% every year. Experts have drawn a correlation between this increase and the increased intensity of UV radiation in Germany. Skin cancer is already one of the most common forms of cancer. In Germany, around 260,000 people develop skin cancer each year, regardless of whether they have light or dark skin. It became clear at the press...

EMA Recommends Limiting the Indications for JAK Inhibitors
https://www.medscape.com/viewarticle/984399

Nov 21st, 2022 - AMSTERDAM — In an effort to minimize the risk of serious side effects associated with Janus kinase (JAK) inhibitors, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended limiting the indications for which these medicines are used — namely chronic inflammatory disorders, such as rheumatoid arthritis, psoriatic arthritis, juvenile idiopathi...

First Classification Criteria Proposed for Chronic Osteomyelitis
https://www.medscape.com/viewarticle/984314

Nov 18th, 2022 - PHILADELPHIA — An international group of researchers has proposed the first classification criteria for chronic nonbacterial osteomyelitis (CNO) and a severe form of it, chronic recurrent multifocal osteomyelitis (CRMO). CNO/CRMO most frequently affect children and adolescents and can significantly affect quality of life. Dr Yongdong (Dan) Zhao Yongdong (Dan) Zhao, MD, PhD, a pediatric rheumato...

Atezolizumab Fails to Improve Outcomes in Postsurgery Kidney Cancer
https://www.medscape.com/viewarticle/984341

Nov 18th, 2022 - Adjuvant immunotherapy with atezolizumab for patients with renal cell carcinoma who have had a nephrectomy with or without a metastasectomy, failed to improve clinical outcomes in a group of patients who are at high risk of recurrence, finds a new international study conducted across 28 countries. The study, called IMmotion010 and published in The Lancet, was a randomized, double-blind, multice...

Immunogen's $6220 Ovarian Cancer Drug to Be Shipped Within Days
https://www.medscape.com/viewarticle/984136

Nov 16th, 2022 - (Reuters) - Drugmaker Immunogen said on Tuesday it would sell its newly approved ovarian cancer drug at a list price of $6,220 per vial and start shipping it "in a matter of days". Most patients will receive three to four vials of Elahere per treatment cycle, putting the cost at about $18,500 to $25,000 a cycle, Immunogen Chief Executive Mark Enyedy said on a conference call. Elahere will be ad...

Debulking Surgery Should Come Soon After NACT in Ovarian Cancer
https://www.medscape.com/viewarticle/984119

Nov 16th, 2022 - The study covered in this summary was published on researchsquare.com as a preprint and has not yet been peer reviewed. Key Takeaway Survival outcomes for patients with high-grade serous ovarian carcinoma may be better when interval debulking surgery is performed within a month of neoadjuvant chemotherapy (NACT). Why This Matters Interval debulking surgery following NACT has gained ground in th...

FDA Approves Mirvetuximab Soravtansine for Folate Receptor Alpha–Positive Ovarian Cancer
https://www.medscape.com/viewarticle/984055

Nov 15th, 2022 - The US Food and Drug Administration (FDA) has granted accelerated approval to mirvetuximab soravtansine (Elahere) for use in pretreated patients with folate receptor (FR) alpha–positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer. These patients can have received one to three prior lines of treatment. "Continued approval may be contingent upon verificat...

The Changes Made in the New Expert Consensus on H pylori
https://www.medscape.com/viewarticle/984066

Nov 15th, 2022 - VIENNA ― Experts in Maastricht, the Netherlands, have updated the 2017 Helicobacter pylori consensus report, now referred to as the Maastricht VI/Florence Consensus Report. Published in August 2022, the document and its changes were recently addressed at the 30th United European Gastroenterology Week in Vienna, Austria. H pylori Gastritis Is an Infectious Disease H pylori infects more than half...

FDA Warning Letter Cites Abraxane Manufacturing Sterility Issues
https://www.medscape.com/viewarticle/984086

Nov 15th, 2022 - The US Food and Drug Administration (FDA) has sent a warning letter to Abraxis BioScience, which manufactures the chemotherapy drug Abraxane (paclitaxel), citing ongoing contamination hazards since 2021. The warning letter, issued October 31, followed an FDA inspection conducted at the company's Phoenix facility from March 28 to April 6 of this year. The inspection found "significant violations...

GSK's Oncology Business Suffers Fresh Blow With Zejula Setback
https://www.medscape.com/viewarticle/983899

Nov 14th, 2022 - (Reuters) - Britain's GSK said on Friday it would limit the use of its ovarian cancer drug Zejula in the United States as a second treatment option to keep cancer at bay in patients whose tumours carry certain mutations. The news marks a second setback for GSK's oncology portfolio this week, after the company on Monday revealed its blood cancer drug Blenrep failed to outperform an older therapy...

First Recommendations for Cancer Screening in Myositis Issued
https://www.medscape.com/viewarticle/983972

Nov 12th, 2022 - PHILADELPHIA – The first consensus screening guidelines for patients with idiopathic inflammatory myopathy (IIM) provide recommendations on risk stratification for individuals, basic and enhanced screening protocols, and screening frequency. Alexander Oldroyd PhD The recommendations, issued by the International Myositis Assessment and Clinical Studies Group (IMACS), stratify cancer risk for ind...

Chronic HBV Infections Associated With a Range of Liver Malignancies
https://www.medscape.com/viewarticle/983968

Nov 12th, 2022 - Untreated chronic hepatitis B infections are associated with increased risks of most major extrahepatic cancer types, shows a new study conducted in South Korea. In this study, which was published in the Journal of Clinical Oncology, researchers found that long-term treatment with nucleos(t)ide analogues (NAs) for patients with chronic hepatitis B lowered their risk of developing extrahepatic c...

Brentuximab in Pediatric Hodgkin Lymphoma: 'Paradigm Shift' and Just Approved
https://www.medscape.com/viewarticle/983923

Nov 11th, 2022 - New results from a trial in pediatric Hodgkin lymphoma have been described as a "paradigm shift" that will change practice, and have just led to approval by the US Food and Drug Administration (FDA) for a new indication for brentuximab vedotin (Adcetris). In the trial, adding brentuximab vedotin to standard chemotherapy provided superior efficacy versus chemotherapy alone for first-line treatme...

Substance Abuse History Tied to Increased Risk of Death From Other Illnesses
https://www.medscape.com/viewarticle/983955

Nov 11th, 2022 - Patients hospitalized for substance use disorder (SUD) are significantly more likely to die from other medical conditions later in life, a new study suggests. Researchers looked at mortality following a diagnosis of 28 different medical conditions, including heart failure, cancer, diabetes, multiple sclerosis, and stroke, and found patients with a history of alcohol or drug misuse had a signifi...

Cancer Death Rates High in American Indians and Alaska Natives
https://www.medscape.com/viewarticle/983842

Nov 10th, 2022 - Mortality rates from cancer among American Indian and Alaska Native (AIAN) patients are 18% higher than for White patients despite similar rates of cancer incidence overall, new research shows. For the most common cancer types — breast, prostate, and lung cancer and colorectal cancer (CRC) — the data show that AIAN individuals have mortality rates that are 8%-42% higher than those in White indi...

Medicaid Coverage of HPV Vaccine in Adults: Implications in Dermatology
https://www.medscape.com/viewarticle/983857

Nov 10th, 2022 - A majority of states cover human papillomavirus vaccination through age 45 years with no need for prior authorization, which has implications for adults with certain dermatologic diseases, according to the authors of a review of Medicaid policies across all 50 states. The human papillomavirus (HPV) vaccine is approved for people aged 9-45 years, for preventing genital, cervical, anal, and oroph...

New FDA Approval Expands Use of Cemiplimab in NSCLC
https://www.medscape.com/viewarticle/983763

Nov 9th, 2022 - A new approval from the US Food and Drug Administration (FDA) expands the use of the immunotherapy PD-1 inhibitor cemiplimab-rwlc (Libtayo) for patients with non–small cell lung cancer (NSCLC). The new indication is for use of cemiplimab in combination with chemotherapy as a first-line treatment for patients with advanced NSCLC and tumors without mutations (no EGFR, ALK, or ROS1 aberrations) wh...

How a Wrong Diagnosis Masked a Young Woman's Cancer
https://www.medscape.com/viewarticle/983732

Nov 8th, 2022 - Two years ago, then 28-year-old Ashley Teague began losing weight. At the time, the Indianapolis, IN, native and mother of two was 6-foot-1 and weighed about 270 pounds. She chalked it up to her busy schedule. She had started a photography business and was travelling "all the time." She didn't know why, but she began losing weight without exercising and without changing her diet, she says.  But...